Loading stock data…
VRTX
$423.92-3.46 (-0.81%)
Market ClosedLast close May 1
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vertex Pharmaceuticals Incorporated in the Healthcare sector is trading at $423.92. The stock is currently 17% below its 52-week high of $509.00, remaining 2.8% below its 200-day moving average. Technical signals show neutral RSI of 35 and bearish MACD signal, explaining why VRTX maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 35) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$423.92
Potential Downside
22.9%
Whystock Fair Value$326.85
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus28 analysts
Buy
Mean target$548.25+29.3%
Range$330.00 – $641.00
Fundamentals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$110.67B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
28.40
Beta
Defensive asset. Lower volatility than the S&P 500.
0.37
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
19.49%
Volume
Today's trading volume
796,426
Recent News
Why CRISPR Therapeutics (CRSP) Is Down 10.1% After Casgevy’s Strong Early Launch Metrics And Earnings Hopes
In late April 2026, analysts highlighted expectations for higher year-over-year earnings and revenue at CRISPR Therapeutics ahead of its March-quarter report, alongside strong launch metrics for Casgevy, the gene therapy it co-commercializes with Vertex Pharmaceuticals. An interesting angle for investors is how Casgevy’s early commercial uptake and growing treated-patient base may influence perceptions of CRISPR Therapeutics’ broader gene-editing platform and revenue potential. With the...
3 Market-Beating Stocks to Consider Right Now
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.
Vertex Gears Up to Report Q1 Earnings: What Investors Can Expect
VRTX heads into Q1 earnings with Trikafta demand, rising Alyftrek sales, and Casgevy and Journavx sales in focus ahead of the May 4 report.
There’s a Revolution in Cancer. But Can Big Pharma Afford It?
Revolution Medicines’ stock has surged on the promise of a pancreatic-cancer drug. With any deal to buy the firm looking unlikely, investors should be prepared for the long haul.
Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for
Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.